___________________________________
Industrial Liaison Group:
Tel: +44 (0) 1235 778797
E-mail: [email protected]
Diamond has recently launched a dedicated facility for Industrial cryo-EM with leading microscope manufacturer Thermo Fisher.
Watch our video featuring Nobel Prize winner, Richard Henderson to see how this world-class facility is impacting science: https://youtu.be/5DEAgrHVZEA
Diamond's high throughput SAXS beamline, B21, reached 100 publications in June this year. Find out how this key research technique can advance your research.
Speeding up the drug discovery process has taken a while to achieve, however Fragment Screening promises to do exactly this. In this article Frank von Delft tells us how Diamond's XChem facility delivers a fast, streamlined process with low overheads for its users.
cryo-EM is a very effective method for studying non-crystalline, dynamic or large macromolecules in their near native state. This growing technique is of much interest to the pharmaceutical sector. Here's why.
A study at Diamond's I04 beamline used crystallography to reveal the structural of S. pnemoniae enzymes, to design next-generation antibiotics and combat respiratory infections. Find out more.
Using Macromolecular Crystallography (MX), scientists at Diamond worked with Heptares Therapeutics to target G-protein-couple receptors (GPCRs) to develop new medicines to target areas such as cancer, central nervous system disorders,diabetes, obesity and pain. Find out more.
On 18th October, our XChem facility on beamline I04-1 diffracted its 100,000th crystal dataset since 2014 - just 1yr for the 2nd 50k! Find out how this technique can advance your research.
A recent article in Nature highlights the growth of cryo-EM for drug discovery and the importance of shared facilities such as eBIC at Diamond in widening access to industry.
The XChem facility @DiamondLightSou provides key information for structure-based drug design. In a recent study we look at how to generate crystals for successful Fragment Screening: Find out more.
State-of-the-art imaging at eBIC helped to gain new insights into the structure of the herpes virus to understand how it infects and replicates within human cells. To find out more, read our article.
Working with GSK, scientists at Diamond have used Macromolecular Crystallography to study RIP2 kinase inhibitors and effectively develop new drugs to combat inflammatory diseases such as Crohn's and Ulcerative Colitis. Find out more.
Using eBIC facilities at Diamond, scientists hope to eradicate polio, by studying their proteins to develop
more efficient vaccines. Find our more.
Using VMXi at Diamond scientists have achieved new insights into an antibody directed against Dengue Fever. Find out more.
Vernalis explains why Macromolecular Crystallography is a key asset in the development of new drugs via structure based drug discovery. Read our case study.
Hear how Fragment Screening has added signifcant value for Evotec at a critical early phase in their drug discovery pathway. Read our case study.
Heptares Therapeutics explain how grid scan techniques on Diamond's MX beamlines is optimising the conditions for GPCR crystallography, maximising the rate at which protein crystals can be scanned and the quality of the data collected. Read our case study.
Crelux explains how the MX mail in service has enabled them to be more efficient and serve their customers better. Read our case study. 
Posters: Introducing our techniques
A collaborative study @DiamondLightSou has successfully determined the crystal structure of human C1ORF123 protein. These results may shed light on the function of the DUF866 protein superfamily, linked to psychotic disorders & brain function. http://bit.ly/2OZ7yER
Scientists @GSK have used #MacromolecularCrystallography@DiamondLightSou to improve targeting of RIP2 Kinase Inhibitors and effectively combat inflammatory diseases such as #Crohn’s and #UlcerativeColitis bit.ly/2OrWh0l #DrugDiscovery
A recent study conducted @DiamondLightSou by @AstraZeneca, uses #MacromolecularCrystallography to target inhibitors and optimise the treatment of #gastrointestinal #stromal #tumours. bit.ly/2pXjSqR #DrugDiscovery#GISTs
“In the last three or four years, pharmaceutical companies have realized that this methodology, cryo-EM, can be used to target previously inaccessible targets.” Dr Richard Henderson tells @SelectScience http://bit.ly/cryo-richhend #eBIC4IOur fantastic #eBIC facilities – the UK’s national #cryoEM facilities allow great insight into #BiologicalResearch and #DrugDevelopment, such as this state-of-the-art imaging, which has given new insight into the herpes simplex virus #Synchrotron bit.ly/HSVeBIC
Techniques available
Diamond Light Source is the UK's national synchrotron science facility, located at the Harwell Science and Innovation Campus in Oxfordshire.
Copyright © 2022 Diamond Light Source
Diamond Light Source Ltd
Diamond House
Harwell Science & Innovation Campus
Didcot
Oxfordshire
OX11 0DE
Diamond Light Source® and the Diamond logo are registered trademarks of Diamond Light Source Ltd
Registered in England and Wales at Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, OX11 0DE, United Kingdom. Company number: 4375679. VAT number: 287 461 957. Economic Operators Registration and Identification (EORI) number: GB287461957003.
Industrial Liaison Office
